Wells Fargo Income Opportunities Fund (NYSE:EAD)
Wells Fargo Income Opportunities Fund (NYSE:EAD) represented a move of 0 percent or $-0.01 per share and closed its previous day trading session at $7.61. 0 Shares were traded in the last trading session with an Average Volume of 201.21 Million Shares. The stock currently has a Market Capitalization of 524.72 Million.
The stock traded between $7.41 and $8.51 over 1-Year time period showing its price to sales ratio of 9.94. Wells Fargo Income Opportunities Fund (NYSE:EAD) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-1.21 and 200-Day Simple Moving Average of $-4.27. Its Price to Free Cash Flow is 0 and Price to Book of 0.85.
Analyst’s recommended the stock as 0 where 1 represents Strong Buy and 5 represents Sell.
Synlogic, Inc. (NASDAQ:SYBX)
In the last trading session, Synlogic, Inc. (NASDAQ:SYBX) added its value by 0% closing at the price of $7.87. The stock currently has market capitalization of 200.06 Million, with average volume of 132.93 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Synlogic, Inc. (NASDAQ:SYBX) is showing beta of 0. This particular value of beta suggests that Synlogic, Inc. (NASDAQ:SYBX) has historically moved 0% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Synlogic, Inc. (NASDAQ:SYBX) is at $-2.29.
The stock currently has RSI of 37.23. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company’s pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders and cancer. It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts.
Synlogic, Inc. (NASDAQ:SYBX) topped its 52-week high price of $15.00 on 01/02/18 and 52-Week Low Price of $ 7.20 on 11/12/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 7.82% and monthly volatility of 8.13% respectively.